Revance Therapeutics, Inc. (RVNC)
$
3.65
Key metrics
Financial statements
Free cash flow per share
-1.8703
Market cap
381 Million
Price to sales ratio
1.5426
Debt to equity
-2.9654
Current ratio
4.1186
Income quality
1.0350
Average inventory
76.8 Million
ROE
1.3365
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Revance Therapeutics, Inc. is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for a range of aesthetic and therapeutic uses both in the United States and internationally. The company's leading candidate, DaxibotulinumtoxinA for injection, has successfully completed Phase III clinical trials targeting glabellar (frown) lines and cervical dystonia. In addition, it is currently undergoing Phase II clinical trials aimed at treating upper facial lines, moderate to severe dynamic forehead lines, and moderate to severe lateral canthal lines. Furthermore, the drug has completed Phase II clinical trials for addressing adult upper limb spasticity and plantar fasciitis. Revance is also exploring DaxibotulinumtoxinA in preclinical trials for migraine treatment and is developing a topical formulation for various indications. Additionally, the company is working on OnabotulinumtoxinA, a biosimilar to BOTOX, through a collaboration and license agreement with Viatris Inc. The company's financial profile reveals an interest income of $13,285,000.00 showcasing its financial investments. Moreover, Revance reported selling, general, and administrative expenses of $292,238,000.00 reflecting its operational overhead costs. The company's income before tax stood at -$323,686,000.00 highlighting its pre-tax profitability, while a notable revenue of $234,040,000.00 underscores its consistent growth. Despite these positive indicators, the company experienced a net loss of -$323,986,000.00 pointing to challenges within its operations. In the stock market, Revance Therapeutics, Inc. holds an appealing position, with shares being affordable at $3.65 making it suitable for budget-conscious investors. The stock boasts a high average trading volume of 2,958,312.00 indicating robust liquidity, which may attract more investors and contribute to price stability. With a market capitalization of $381,023,500.00 the company is categorized as a small-cap player, allowing it flexibility and growth potential in a dynamic market. As a significant contributor in the Biotechnology industry, Revance plays a pivotal role in shaping the overall market landscape. Additionally, it belongs to the Healthcare sector, where it is driving innovation and growth, thus appealing to a wide range of investors looking for opportunities in emerging biotechnology ventures.
What is Revance Therapeutics, Inc. (RVNC)'s stock forecast?
Analysts predict Revance Therapeutics, Inc. stock to fluctuate between $2.30 (low) and $7.56 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Revance Therapeutics, Inc.'s market capitalization?
As of 2025-02-05, Revance Therapeutics, Inc.'s market cap is $381,023,500, based on 104,390,000 outstanding shares.
How does Revance Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Revance Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Revance Therapeutics, Inc. (RVNC) stock?
To buy Revance Therapeutics, Inc. (RVNC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for RVNC. Place an order (Market, Limit, etc.).
What is the best time to invest in Revance Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Revance Therapeutics, Inc. perform in the last earnings report?
Revenue: $234,040,000 | EPS: -$3.83 | Growth: -21.84%.
Where can I find Revance Therapeutics, Inc.'s investor relations reports?
Visit https://www.revance.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Revance Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Revance Therapeutics, Inc. stock?
All-time high: $42.41 (2015-11-11) | All-time low: $2.30 (2024-06-26).
What are the key trends affecting Revance Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (NASDAQ:RVNC) on behalf of long-term stockholders following a class action complaint that was filed against Revance on January 3, 2025 with a Class Period from February 29, 2024 to December 6, 2024. Our investigation concerns whether the board of directors of Revance have breached their fiduciary duties to the company.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133949&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133907&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Revance Therapeutics, Inc. (NASDAQ:RVNC) between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), of the important March 4, 2025 lead plaintiff deadline. SO WHAT: If you purchased Revance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133865&wire=1 or contact Joseph E. Levi, Esq.
prnewswire.com
NEW YORK , March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133758&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133725&wire=1 or contact Joseph E. Levi, Esq.
globenewswire.com
SAN JOSE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between February 29, 2024 and December 6, 2024, both dates inclusive (the “Class Period”), of the important March 4, 2025 lead plaintiff deadline.
See all news
